{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:01:08Z","timestamp":1773226868813,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"American Legion and Auxiliary Heart Research Foundation"},{"name":"National Institute of Health","award":["AI-65289"],"award-info":[{"award-number":["AI-65289"]}]},{"name":"National Institute of Health","award":["HD38416-01"],"award-info":[{"award-number":["HD38416-01"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T03:30:29Z","timestamp":1373945429000},"page":"2756-2762","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model"],"prefix":"10.1016","volume":"32","author":[{"given":"Mark R.","family":"Schleiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jodi","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janine Gessner","family":"Mash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Wettendorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Mossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.07.010_bib0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1045-1870(99)80021-1","article-title":"Congenital cytomegalovirus infection and disease","volume":"10","author":"Demmler","year":"1999","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0010","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s11940-002-0039-8","article-title":"Congenital Cytomegalovirus Infection","volume":"4","author":"Bale","year":"2002","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0015","series-title":"Vaccines for the 21st century: a tool for decisionmaking","author":"Institute of Medicine (US), Committee to Study Priorities for Vaccine Development","year":"1999"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0020","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.4.3.381","article-title":"Progress toward an elusive goal: current status of cytomegalovirus vaccines","volume":"4","author":"Schleiss","year":"2005","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0025","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0030","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","article-title":"Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers","volume":"28","author":"Bernstein","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/clinids\/5.2.177","article-title":"Cytomegaloviral infections in the guinea pig: experimental models for human disease","volume":"5","author":"Bia","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0045","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ilar.47.1.65","article-title":"Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns","volume":"47","author":"Schleiss","year":"2006","journal-title":"ILAR J"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0050","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1128\/JVI.55.2.402-409.1985","article-title":"The placenta as a site of cytomegalovirus infection in guinea pigs","volume":"55","author":"Griffith","year":"1985","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0055","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2174\/187152611797636721","article-title":"Congenital cytomegalovirus infection: molecular mechanisms mediating viral pathogenesis","volume":"11","author":"Schleiss","year":"2011","journal-title":"Infect Disord Drug Targets"},{"issue":"Suppl. A","key":"10.1016\/j.vaccine.2013.07.010_bib0060","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.placenta.2006.11.002","article-title":"Animal models of human placentation\u2014a review","volume":"28","author":"Carter","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0065","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1055\/s-0029-1211275","article-title":"Placental structure: in a comparative aspect","volume":"102","author":"Leiser","year":"1994","journal-title":"Exp Clin Endocrinol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0070","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.placenta.2007.02.005","article-title":"The Guinea pig placenta: model of placental growth dynamics","volume":"28","author":"Mess","year":"2007","journal-title":"Placenta"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0075","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/rmv.475","article-title":"Neuropathogenesis in cytomegalovirus infection: indication of the mechanisms using mouse models","volume":"15","author":"Tsutsui","year":"2005","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1086\/379839","article-title":"Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection","volume":"188","author":"Schleiss","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0085","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1086\/382751","article-title":"Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine","volume":"189","author":"Schleiss","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0090","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems","volume":"10","author":"Gar\u00e7on","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0095","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0100","doi-asserted-by":"crossref","first-page":"913","DOI":"10.4161\/hv.7.9.16225","article-title":"Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency","volume":"7","author":"Surquin","year":"2011","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0166-0934(02)00258-6","article-title":"Cloning and expression of the guinea pig cytomegalovirus glycoprotein B (gB) in a recombinant baculovirus: utility for vaccine studies for the prevention of experimental infection","volume":"108","author":"Schleiss","year":"2003","journal-title":"J Virol Met"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1089\/vim.2000.13.137","article-title":"Maternal IgG avidity and IgM detected by blot as diagnostic tools to identify pregnant women at risk of transmitting cytomegalovirus","volume":"13","author":"Lazzarotto","year":"2000","journal-title":"Viral Immunol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0115","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1006\/biol.1996.0004","article-title":"An enzyme immunoassay based micro-neutralization test for titration of antibodies to human cytomegalovirus (CMV) and its correlation with direct ELISA measuring CMV IgG antibodies","volume":"24","author":"Gupta","year":"1996","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0120","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1128\/JVI.64.3.1079-1085.1990","article-title":"Cell surface expression of human cytomegalovirus (HCMV) gp 55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response","volume":"64","author":"Britt","year":"1990","journal-title":"J Virol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2013.07.010_bib0125","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S1386-6532(02)00100-2","article-title":"Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV)","volume":"25","author":"Schleiss","year":"2002","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0130","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.200425203","article-title":"Cross-reactive recognition of human and primate cytomegalovirus sequences by human CD4 cytotoxic T lymphocytes specific for glycoprotein B and H","volume":"34","author":"Elkington","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0135","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0140","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/vir.0.83523-0","article-title":"Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial\/epithelial cells, but not fibroblasts, early during primary infection","volume":"89","author":"Gerna","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0145","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.vaccine.2007.12.038","article-title":"Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers","volume":"26","author":"Vandepapeli\u00e8re","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0150","doi-asserted-by":"crossref","first-page":"7016","DOI":"10.1016\/j.vaccine.2010.08.035","article-title":"Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems","volume":"28","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0155","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"Kester","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0160","doi-asserted-by":"crossref","first-page":"e25786","DOI":"10.1371\/journal.pone.0025786","article-title":"Circumsporozoite-specific T cell responses in children vaccinated with RTS,S\/AS01E and protection against P falciparum clinical malaria","volume":"6","author":"Olotu","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2013.07.010_bib0165","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm1009","article-title":"A CD4+ T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease","volume":"10","author":"Reece","year":"2004","journal-title":"Nat Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13009328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13009328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T21:00:54Z","timestamp":1596142854000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13009328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X13009328"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoprotein B (gB) vaccines adjuvanted with AS01 or AS02 protect female guinea pigs against cytomegalovirus (CMV) viremia and offspring mortality in a CMV-challenge model","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}